This Phase 1/2, open label, dose escalation and cohort expansion study is designed to evaluate and characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of JK08 administered subcutaneously in patients with unresectable locally, advanced or metastatic cancer.~The study consists of a Dose Escalation phase to determine the maximum tolerated dose/recommended phase 2 dose of JK08, followed by a Cohort Expansion phase to further define the safety and initial efficacy of JK08 in three tumor specific cohorts (melanoma, colorectal cancer, and breast cancer) and a basket cohort of mixed solid tumors.
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer.